RESEARCH TRIANGLE PARK, N.C.,
Nov. 9, 2015 /PRNewswire/ --
GlaxoSmithKline plc (LSE: GSK) today announced a tweet chat with
the COPD Foundation and American Association for Respiratory Care
(AARC) to raise awareness and education of COPD. Happening
today at noon Eastern, the chat will pose and discuss questions as
it relates to COPD management, optimal treatment outcomes, and
improving the patient/physician dialogue. To participate in the
tweet chat, participants can use the hashtag #COPDChat on
Twitter.
COPD is a growing problem in the U.S. and in one decade has
risen from the fourth leading cause of death to the third, after
heart disease and cancer.1 Although COPD is not curable,
it is important for patients to understand that it is both
manageable and treatable. Through early discussions with a primary
care physician or pulmonologist, it is possible for patients to
receive early diagnosis and begin building proper nutrition,
exercise and treatment plans unique to their lifestyle and
favorable for decreased disease progression.2,3
5.5 percent of U.S. health costs are spent on chronic lung
disease with a total of $49.9 billion
annual costs accounting for COPD alone.4,5,6
Additionally, 26 percent of U.S. respondents reported visiting the
emergency room with 17 percent having been hospitalized in
2014.7
During the #COPDChat, GSK, AARC and the COPD Foundation will be
joined by knowledgeable healthcare providers, eager and ready to
discuss expert information on COPD and how to better manage the
disease so patients are able to maintain a healthy and comfortable
quality of life.
"By joining together with two leading advocacy organizations,
our hope is to increase knowledge and awareness surrounding a
disease that affects almost 15 million Americans," said
Deborah Long, U.S. Medical Affairs
Lead, GSK. "We welcome healthcare providers, patients and friends
and family of those diagnosed to participate in the chat to gain a
better of understanding of COPD management."
"The American Association for Respiratory Care is proud to be a
part of this COPD Chat. It is essential that respiratory therapists
be part of the conversation, it is all about our patients," said
Tom Kallstrom, MBA, RRT, FAARC, AARC
Executive Director.
GSK invites patients, families, and healthcare providers, along
with the rest of the COPD community to join us and discuss COPD
during #COPDChat on Twitter, Monday,
November 9, at 12 PM
ET.
"We are so pleased to be collaborating with AARC and GSK on this
initiative. This is a great opportunity to connect the key
stakeholders in our community from across the globe during COPD
Awareness month," said John W.
Walsh, President and Co-Founder of the COPD Foundation. "I
encourage providers, patients and caregivers to lend their voice to
the COPD Chat."
For more information on COPD, visit COPD.com, COPD360.org, or
AARC.org.
About COPD
COPD is a disease of the lungs that
includes chronic bronchitis, emphysema or both. COPD is
characterised by obstruction to airflow that interferes with normal
breathing. COPD is thought to affect around 329 million people
worldwide.8
Long-term exposure to lung irritants that damage the lungs and
the airways are usually the cause of COPD. Cigarette smoke,
breathing in second hand smoke, air pollution, chemical fumes or
dust from the environment or workplace can all contribute to COPD.
Most people who have COPD are at least 40 years old when symptoms
begin.9
About COPD Foundation
The COPD Foundation's mission is to prevent and cure chronic
obstructive pulmonary disease and improve the lives of all people
affected by COPD. The Foundation's activities focus on achieving
these results through research, education and advocacy
programs. To learn more or get involved, call the C.O.P.D.
Information Line at 1-866-316-COPD (2673) or join
www.copd360social.org.
About AARC
The American Association for Respiratory Care (AARC) is a
not-for-profit, professional organization, consisting of 50,000
respiratory therapists, physicians, and other health care
professionals. AARC is dedicated to assisting persons with
respiratory diseases receive safe and effective respiratory care.
The AARC also publishes RESPIRATORY CARE, a peer-reviewed
scientific journal listed in Index Medicus.
GSK – one of the world's leading research-based
pharmaceutical and healthcare companies – is committed to improving
the quality of human life by enabling people to do more, feel
better and live longer. For further information please visit
www.gsk.com.
GSK
enquiries:
|
|
|
|
UK Media
enquiries:
|
David
Mawdsley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Simon
Steel
|
+44 (0) 20 8047 5502
|
(London)
|
|
David
Daley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Catherine
Hartley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Sarah
Spencer
|
+44 (0) 20 8047 5502
|
(London)
|
|
Claire
Brough
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
|
|
US Media
enquiries:
|
Sarah
Alspach
|
+1 202 715 1048
|
(Washington,
DC)
|
|
Mary Anne
Rhyne
|
+1 919 483 0492
|
(North
Carolina)
|
|
Melinda
Stubbee
|
+1 919 483 2510
|
(North
Carolina)
|
|
Jenni
Ligday
|
+1 202 715 1049
|
(Washington,
DC)
|
|
Karen
Hagens
|
+1 919 483 2863
|
(North
Carolina)
|
|
Gwynn
Oosterbaan
|
+1 215 751 7468
|
(Philadelphia)
|
|
|
|
|
Analyst/Investor
enquiries:
|
Ziba
Shamsi
|
+44 (0) 20 8047 5543
|
(London)
|
|
Tom Curry
|
+ 1 215 751 5419
|
(Philadelphia)
|
|
Gary
Davies
|
+44 (0) 20 8047 5503
|
(London)
|
|
James
Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Jeff
McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary
statement regarding forward-looking statements GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D 'Risk factors' in the
company's Annual Report on Form 20-F for 2014.
|
Registered in
England & Wales:
No.
3888792
|
|
Registered
Office:
980 Great West
Road
Brentford,
Middlesex
TW8 9GS
|
1 National Heart, Lung, and Blood Institute. Take the
first step to breathing better. Available from
www.nhlbi.nih.gov/health/public/lung/copd/index.htm. [Last Accessed
October 2015]
2 Everyday Health. Can You Stop the Progression of COPD?
http://www.everydayhealth.com/hs/chronic-obstructive-pulmonary-disease/can-you-stop-progression-of-copd/.
[Last Accessed October 2015]
3 NIH Medline Plus. COPD: When You Learn More, You'll
Breathe Better.
https://www.nlm.nih.gov/medlineplus/magazine/issues/winter07/articles/winter07pg24-25.html.
[Last Accessed October 2015]
4 NIH National Heart, Lung, and Blood Institute.
Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung
and Blood Diseases. Available at
http://www.nhlbi.nih.gov/files/docs/research/2012_ChartBook_508.pdf.
[Last accessed October 2015].
5 Centers for Disease Control and Prevention.
Health Expenditures. Atlanta, GA:
Centers for Disease Control and Prevention, 2011.
6 The American Lung Association. Epidemiology and
Statistics Unit. Trends in COPD (Chronic Bronchitis and Emphysema):
Morbidity and Morality. March
2013.
7 Landis, SH. et al.
Continuing to Confront COPD International Patient Survey: methods,
COPD prevalence, and disease burden in 2012–2013. International
Journal of COPD, June 2014.
8 Global, regional, and national incidence, prevalence,
and years lived with disability for 301 acute and chronic diseases
and injuries in 188 countries, 1990–2013: a systematic analysis for
the Global Burden of Disease Study 2013. The Lancet; 2015.
Available at: http://dx.doi.org/10.1016/S0140-6736(15)60692-4.
[Last Accessed September 2015].
9 National Heart Lung and Blood Institute. Who is at
risk for COPD? Available
at:https://www.nhlbi.nih.gov/health/health-topics/topics/copd/atrisk.html.
[Last Accessed September 2015].
Photo - http://photos.prnewswire.com/prnh/20151106/284738
Logo - http://photos.prnewswire.com/prnh/20151106/284739LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/gsk-copd-foundation-and-aarc-team-up-for-copdchat-november-9th-12-pm-et-300174499.html
SOURCE GlaxoSmithKline plc